Home
About
- Company
- Careers
Technology
Pipeline
Collaboration
News
Contact

Menu

Home
About
- Company
- Careers
Technology
Pipeline
Collaboration
News
Contact

Search

Close

中文

Menu

中文

Company

Home > Company

Our Vision
Company Profile
Management Team
Journey & Honors

Menu

Our Vision
Company Profile
Management Team
Journey & Honors

We are committed to leading the development of new drugs for the treatment of genitourinary tumors and other major diseases

Links

Company
Technology
Pipeline
Collaboration
News
Careers
Contact

News

Now Hiring: Scientist / Senior Scientist (San Francisco)
Asieris Pharmaceuticals Lands on STAR Market
World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
Bladder cancer diagnosis drug Hexvix® completed first patient procedure in Bo’ao Lecheng
Now Hiring: Biology Director (San Francisco)
The CDE Approved IND Application to Investigate Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients
Asieris Named One of Top 30 Chinese Innovative Enterprises in Small Molecule Drugs

Contact

info@asieris.com
USA
201 King of Prussia Rd
Suite 650
Radnor, PA 19087
China
8F Building 56
1000 Jinhai Rd
Pudong, Shanghai

Join Us

Partner with us

Copyright © 2014-2022 Asieris Pharmaceuticals. All Rights Reserved.